{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T02:12:26Z","timestamp":1790820746065,"version":"4.1.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T00:00:00Z","timestamp":1774396800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T00:00:00Z","timestamp":1774396800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100007343","name":"Universit\u00e0 degli Studi di Brescia","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100007343","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s00259-026-07862-x","type":"journal-article","created":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T00:18:57Z","timestamp":1774397937000},"page":"5243-5250","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["The predictive and prognostic role of baseline 2-[18F]FDG PET\/CT volumetric and dissemination features in classical Hodgkin lymphoma"],"prefix":"10.1007","volume":"53","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0810-6494","authenticated-orcid":false,"given":"Domenico","family":"Albano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1156-6395","authenticated-orcid":false,"given":"Alessandro","family":"Re","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-4391-7673","authenticated-orcid":false,"given":"Rosa","family":"Daffini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3052-7463","authenticated-orcid":false,"given":"Alessandra","family":"Tucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2980-5964","authenticated-orcid":false,"given":"Francesco","family":"Bertagna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,25]]},"reference":[{"issue":"11","key":"7862_CR1","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1016\/j.annonc.2025.07.014","volume":"36","author":"TA Eyre","year":"2025","unstructured":"Eyre TA, Cwynarski K, d\u2019Amore F, de Leval L, Dreyling M, Eichenauer DA, et al. Lymphomas: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2025;36(11):1263\u201384. https:\/\/doi.org\/10.1016\/j.annonc.2025.07.014.","journal-title":"Ann Oncol"},{"key":"7862_CR2","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","volume":"32","author":"BD Cheson","year":"2014","unstructured":"Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32:3059\u201367. https:\/\/doi.org\/10.1200\/JCO.2013.54.8800.","journal-title":"J Clin Oncol"},{"key":"7862_CR3","doi-asserted-by":"publisher","unstructured":"Barrington SF, Mikhaeel NG, Kostakoglu L, Meignan M, Hutchings M, M\u00fceller SP et al. Role of imaging in the staging and response assessment of lymphoma: consensus of the international conference on malignant lymphomas imaging working group. J Clin Oncol. 2014;32:3048\u201358. https:\/\/doi.org\/10.1200\/JCO.2013.53.5229","DOI":"10.1200\/JCO.2013.53.5229"},{"key":"7862_CR4","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1038\/s41571-023-00799-2","volume":"20","author":"JP Alderuccio","year":"2023","unstructured":"Alderuccio JP, Kuker RA, Yang F, Moskowitz CH. Quantitative PET-based biomarkers in lymphoma: getting ready for primetime. Nat Rev Clin Oncol. 2023;20:640\u201357. https:\/\/doi.org\/10.1038\/s41571-023-00799-2.","journal-title":"Nat Rev Clin Oncol"},{"issue":"10","key":"7862_CR5","doi-asserted-by":"publisher","first-page":"3198","DOI":"10.1007\/s00259-021-05233-2","volume":"48","author":"R Frood","year":"2021","unstructured":"Frood R, Burton C, Tsoumpas C, Frangi AF, Gleeson F, Patel C, et al. Baseline PET\/CT imaging parameters for prediction of treatment outcome in Hodgkin and diffuse large B cell lymphoma: a systematic review. Eur J Nucl Med Mol Imaging. 2021;48(10):3198\u2013220. https:\/\/doi.org\/10.1007\/s00259-021-05233-2.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"7862_CR6","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1097\/RLU.0000000000004930","volume":"49","author":"M Mouheb","year":"2024","unstructured":"Mouheb M, Pierre-Jean M, Devillers A, Ferm\u00e9 C, Benchalal M, Manson G, et al. Prognostic Value of Baseline Tumor Burden and Tumor Dissemination Extracted From 18 F-FDG PET\/CT in a Cohort of Adult Patients With Early or Advanced Hodgkin Lymphoma. Clin Nucl Med. 2024;49(1):e1\u20135. https:\/\/doi.org\/10.1097\/RLU.0000000000004930.","journal-title":"Clin Nucl Med"},{"key":"7862_CR7","doi-asserted-by":"publisher","first-page":"6347404","DOI":"10.1155\/2021\/6347404","volume":"2021","author":"Y Zhou","year":"2021","unstructured":"Zhou Y, Zhu Y, Chen Z, Li J, Sang S, Deng S. Radiomic Features of 18F-FDG PET in Hodgkin Lymphoma Are Predictive of Outcomes. Contrast Media Mol Imaging. 2021;2021:6347404. https:\/\/doi.org\/10.1155\/2021\/6347404.","journal-title":"Contrast Media Mol Imaging"},{"key":"7862_CR8","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1002\/hon.3025","volume":"40","author":"R Durmo","year":"2022","unstructured":"Durmo R, Donati B, Rebaud L, Cottereau AS, Ruffini A, Nizzoli ME, et al. Prognostic value of lesion dissemination in doxorubicin, bleomycin, vinblastine, and dacarbazine-treated, interimPET-negative classical Hodgkin Lymphoma patients: a radio-genomic study. Hematol Oncol. 2022;40:645\u201357. https:\/\/doi.org\/10.1002\/hon.3025.","journal-title":"Hematol Oncol"},{"key":"7862_CR9","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1007\/s00277-023-05547-1","volume":"103","author":"A Aksu","year":"2024","unstructured":"Aksu A, K\u00fc\u00e7\u00fcker KA, Solmaz S, Turgut B. A different perspective on PET\/CT before treatment in patients with Hodgkin lymphoma: importance of volumetric and dissemination parameters. Ann Hematol. 2024;103:813\u201322. https:\/\/doi.org\/10.1007\/s00277-023-05547-1.","journal-title":"Ann Hematol"},{"issue":"2","key":"7862_CR10","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1007\/s00259-014-2961-x","volume":"42","author":"R Boellaard","year":"2015","unstructured":"Boellaard R, Delgado-Bolton R, Oyen WJG, Giammarile F, Tatsch K, Eschner W, et al. FDG PET\/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imag. 2015;42(2):328\u201354.","journal-title":"Eur J Nucl Med Mol Imag"},{"issue":"16","key":"7862_CR11","doi-asserted-by":"publisher","first-page":"4786","DOI":"10.1158\/0008-5472.CAN-18-0125","volume":"78","author":"C Nioche","year":"2018","unstructured":"Nioche C, Orlhac F, Boughdad S, Reuz\u00e9 S, Goya-Outi J, Robert C, et al. LIFEx: A Freeware for Radiomic Feature Calculation in Multimodality Imaging to Accelerate Advances in the Characterization of Tumor Heterogeneity. Cancer Res. 2018;78(16):4786\u20139. https:\/\/doi.org\/10.1158\/0008-5472.CAN-18-0125.","journal-title":"Cancer Res"},{"issue":"4","key":"7862_CR12","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1007\/s12149-019-01338-9","volume":"33","author":"D Albano","year":"2019","unstructured":"Albano D, Re A, Tucci A, Giubbini R, Bertagna F. Prognostic role of \u2206MTV and \u2206TLG in Burkitt lymphoma. Ann Nucl Med. 2019;33(4):280\u20137. https:\/\/doi.org\/10.1007\/s12149-019-01338-9.","journal-title":"Ann Nucl Med"},{"issue":"5","key":"7862_CR13","doi-asserted-by":"publisher","first-page":"498","DOI":"10.3390\/medicina57050498","volume":"57","author":"D Albano","year":"2021","unstructured":"Albano D, Dondi F, Mazzoletti A, Bellini P, Giubbini R, Bertagna F. Prognostic Impact of Pretreatment 2-[18F]-FDG PET\/CT Parameters in Primary Gastric DLBCL. Med (Kaunas). 2021;57(5):498. https:\/\/doi.org\/10.3390\/medicina57050498.","journal-title":"Med (Kaunas)"},{"issue":"5","key":"7862_CR14","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.3390\/jcm11051210","volume":"11","author":"D Albano","year":"2022","unstructured":"Albano D, Pasinetti N, Dondi F, Giubbini R, Tucci A, Bertagna F. Prognostic Role of Pre-Treatment Metabolic Parameters and Sarcopenia Derived by 2-[18F]-FDG PET\/CT in Elderly Mantle Cell Lymphoma. J Clin Med. 2022;11(5):1210. https:\/\/doi.org\/10.3390\/jcm11051210.","journal-title":"J Clin Med"},{"issue":"21","key":"7862_CR15","doi-asserted-by":"publisher","first-page":"4504","DOI":"10.1182\/bloodadvances.2021005150","volume":"5","author":"U Ricardi","year":"2021","unstructured":"Ricardi U, Levis M, Evangelista A, Gioia DM, Sacchetti GM, Gotti M, et al. Role of radiotherapy to bulky sites of advanced Hodgkin lymphoma treated with ABVD: final results of FIL HD0801 trial. Blood Adv. 2021;5(21):4504\u201314.","journal-title":"Blood Adv"},{"issue":"9","key":"7862_CR16","doi-asserted-by":"publisher","first-page":"2494","DOI":"10.3390\/cancers15092494","volume":"15","author":"D Albano","year":"2023","unstructured":"Albano D, Treglia G, Dondi F, Calabr\u00f2 A, Rizzo A, Annunziata S, et al. 18F-FDG PET\/CT Maximum Tumor Dissemination (Dmax) in Lymphoma: A New Prognostic Factor? Cancers (Basel). 2023;15(9):2494. https:\/\/doi.org\/10.3390\/cancers15092494.","journal-title":"Cancers (Basel)"},{"key":"7862_CR17","doi-asserted-by":"publisher","first-page":"1726567","DOI":"10.3389\/fmed.2025.1726567","volume":"12","author":"S Tasevski","year":"2026","unstructured":"Tasevski S, Treglia G, Marin A, Bertagna F, Albano D. The prognostic role of maximum tumor dissemination derived by PET\/CT in oncological diseases: a systematic review. Front Med (Lausanne). 2026;12:1726567. https:\/\/doi.org\/10.3389\/fmed.2025.1726567.","journal-title":"Front Med (Lausanne)"},{"key":"7862_CR18","doi-asserted-by":"publisher","first-page":"1515040","DOI":"10.3389\/fmed.2024.1515040","volume":"11","author":"D Albano","year":"2024","unstructured":"Albano D, Ravanelli M, Durmo R, Versari A, Filice A, Rizzo A, et al. Semiquantitative 2-[18F]FDG PET\/CT-based parameters role in lymphoma. Front Med (Lausanne). 2024;11:1515040. https:\/\/doi.org\/10.3389\/fmed.2024.1515040.","journal-title":"Front Med (Lausanne)"},{"issue":"12","key":"7862_CR19","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.2967\/jnumed.121.263501","volume":"63","author":"KB Girum","year":"2022","unstructured":"Girum KB, Rebaud L, Cottereau AS, Meignan M, Clerc J, Vercellino L, et al. 18F-FDG PET Maximum-Intensity Projections and Artificial Intelligence: A Win-Win Combination to Easily Measure Prognostic Biomarkers in DLBCL Patients. J Nucl Med. 2022;63(12):1925\u201332. https:\/\/doi.org\/10.2967\/jnumed.121.263501.","journal-title":"J Nucl Med"},{"issue":"3","key":"7862_CR20","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1016\/j.annonc.2020.11.019","volume":"32","author":"AS Cottereau","year":"2021","unstructured":"Cottereau AS, Meignan M, Nioche C, Capobianco N, Clerc J, Chartier L, et al. Risk stratification in diffuse large B-cell lymphoma using lesion dissemination and metabolic tumor burden calculated from baseline PET\/CT\u2020. Ann Oncol. 2021;32(3):404\u201311. https:\/\/doi.org\/10.1016\/j.annonc.2020.11.019.","journal-title":"Ann Oncol"},{"issue":"9","key":"7862_CR21","doi-asserted-by":"publisher","first-page":"3180","DOI":"10.1007\/s00259-025-07176-4","volume":"52","author":"S Malmon","year":"2025","unstructured":"Malmon S, Elsensohn MH, Thieblemont C, Morschhauser F, Casasnovas O, Andr\u00e9 M, et al. Prognostic impact of metabolic tumor volume using the SUV4.0 segmentation threshold in 1,960 lymphoma patients from prospective LYSA trials. Eur J Nucl Med Mol Imaging. 2025;52(9):3180\u20139. https:\/\/doi.org\/10.1007\/s00259-025-07176-4.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"5","key":"7862_CR22","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1007\/s12149-025-02026-7","volume":"39","author":"D Albano","year":"2025","unstructured":"Albano D, Temponi A, Bertagna F, Suardi N, Talin A, Bonu M, et al. The prognostic role of staging [18F]PSMA-1007 PET\/CT volumetric and dissemination features in prostate cancer. Ann Nucl Med. 2025;39(5):518\u201326. https:\/\/doi.org\/10.1007\/s12149-025-02026-7.","journal-title":"Ann Nucl Med"},{"issue":"9","key":"7862_CR23","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.2967\/jnumed.124.267789","volume":"65","author":"R Boellaard","year":"2024","unstructured":"Boellaard R, Buvat I, Nioche C, Ceriani L, Cottereau AS, Guerra L, et al. International Benchmark for Total Metabolic Tumor Volume Measurement in Baseline 18F-FDG PET\/CT of Lymphoma Patients: A Milestone Toward Clinical Implementation. J Nucl Med. 2024;65(9):1343\u20138. https:\/\/doi.org\/10.2967\/jnumed.124.267789.","journal-title":"J Nucl Med"},{"key":"7862_CR24","doi-asserted-by":"publisher","unstructured":"Connors JM, Jurczak W, Straus DJ, Ansell SM, Kim WS, Gallamini A et al. Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin\u2019s Lymphoma. N Engl J Med. 2018;378(4):331\u2013344. https:\/\/doi.org\/10.1056\/NEJMx180007 10.1056\/NEJMoa1708984. Epub 2017 Dec 10. Erratum in: N Engl J Med. 2018;378(9):878.","DOI":"10.1056\/NEJMx180007"},{"key":"7862_CR25","doi-asserted-by":"publisher","unstructured":"Borchmann P, Ferdinandus J, Schneider G, Moccia A, Greil R, Hertzberg M et al. Assessing the efficacy and tolerability of PET-guided BrECADD versus eBEACOPP in advanced-stage, classical Hodgkin lymphoma (HD21): a randomised, multicentre, parallel, open-label, phase 3 trial. Lancet. 2024;404(10450):341\u2013352. doi: 10.1016\/S0140-6736(24)01315-1. Epub 2024 Jul 3. Erratum in: Lancet. 2024;404(10468):2164. https:\/\/doi.org\/10.1016\/S0140-6736(24)02571-6","DOI":"10.1016\/S0140-6736(24)02571-6"},{"issue":"15","key":"7862_CR26","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1056\/NEJMoa2405888","volume":"391","author":"AF Herrera","year":"2024","unstructured":"Herrera AF, LeBlanc M, Castellino SM, Li H, Rutherford SC, Evens AM, et al. Nivolumab\u2009+\u2009AVD in Advanced-Stage Classic Hodgkin\u2019s Lymphoma. N Engl J Med. 2024;391(15):1379\u201389. https:\/\/doi.org\/10.1056\/NEJMoa2405888.","journal-title":"N Engl J Med"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-026-07862-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-026-07862-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-026-07862-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T06:47:50Z","timestamp":1782715670000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-026-07862-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,25]]},"references-count":26,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["7862"],"URL":"https:\/\/doi.org\/10.1007\/s00259-026-07862-x","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,25]]},"assertion":[{"value":"21 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Ethics Committee of CET Lombardia 6, Italy (NP 6211).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval and Consent to participate"}}]}}